Manufacturer Novartis marketed Zometa (zoledronate or zoledronic acid) as a bisphosphonate drug that inhibits the release of calcium from bones.
Zometa is prescribed to patients with multiple myeloma and other cancers and used to prevent osteoporosis and skeletal fractures.
Zometa Linked to ‘Bone Death’
As with Fosamax and Aredia, Zometa has been linked to a high rate of osteonecrosis of the jaw, or “bone death.” Osteonecrosis is a condition characterized by pain, swelling, and bone damage around the tooth sockets. Loss of bone may result in loose teeth, bone spurs, and other problems. Most cases of osteonecrosis of the jaw occur following dental procedures and may have complications, including infection.